Yona Greenman1,2. 1. Institute of Endocrinology, Metabolism, Diabetes and Hypertension, Tel Aviv-Sourasky Medical Center, 6 Weizmann Street, 64239, Tel Aviv, Israel. yonagr@tlvmc.gov.il. 2. Tel Aviv University, Tel Aviv, Israel. yonagr@tlvmc.gov.il.
Abstract
PURPOSE: Treatment goals in prolactinomas are to correct hypogonadism, restore fertility and control tumor mass in case of macroadenomas. According to current guidelines, medical treatment of asymptomatic postmenopausal women is not indicated. The purpose of this study was to review the current literature pertaining to biological behavior of prolactinomas during menopause, likelihood of successful dopamine agonist withdrawal during this period and possible prolactin-mediated increased morbidity that could modify current management. METHODS: A comprehensive literature search including papers published until July 2019 was conducted using PubMed and Medline databases. RESULTS: Women with prolactinomas entering menopause have a higher chance of prolactin normalization of treatment compared with women in their reproductive years. Although most prolactin secreting adenomas diagnosed during menopause are large, they respond well to dopamine agonist treatment. Data directly linking hyperprolactinemia with an increased risk of cancer and cardiovascular and metabolic morbidity are inconsistent. There is no data indicating that correction of hyperprolactinemia improves clinical outcomes in asymptomatic patients bearing microadenomas. CONCLUSION: There is no evidence that justifies changing current recommendations to withhold medical treatment of microprolactinomas in asymptomatic post-menopausal women. Macroprolactinoma patients should be treated according to standard clinical practice.
PURPOSE: Treatment goals in prolactinomas are to correct hypogonadism, restore fertility and control tumor mass in case of macroadenomas. According to current guidelines, medical treatment of asymptomatic postmenopausal women is not indicated. The purpose of this study was to review the current literature pertaining to biological behavior of prolactinomas during menopause, likelihood of successful dopamine agonist withdrawal during this period and possible prolactin-mediated increased morbidity that could modify current management. METHODS: A comprehensive literature search including papers published until July 2019 was conducted using PubMed and Medline databases. RESULTS:Women with prolactinomas entering menopause have a higher chance of prolactin normalization of treatment compared with women in their reproductive years. Although most prolactin secreting adenomas diagnosed during menopause are large, they respond well to dopamine agonist treatment. Data directly linking hyperprolactinemia with an increased risk of cancer and cardiovascular and metabolic morbidity are inconsistent. There is no data indicating that correction of hyperprolactinemia improves clinical outcomes in asymptomatic patients bearing microadenomas. CONCLUSION: There is no evidence that justifies changing current recommendations to withhold medical treatment of microprolactinomas in asymptomatic post-menopausal women. Macroprolactinomapatients should be treated according to standard clinical practice.
Entities:
Keywords:
Breast cancer; Menopause; Osteoporosis; Pituitary adenoma; Prolactin; Prolactinoma
Authors: Shereen Ezzat; Sylvia L Asa; William T Couldwell; Charles E Barr; William E Dodge; Mary Lee Vance; Ian E McCutcheon Journal: Cancer Date: 2004-08-01 Impact factor: 6.860
Authors: Jun Li; Megan S Rice; Tianyi Huang; Susan E Hankinson; Charles V Clevenger; Frank B Hu; Shelley S Tworoger Journal: Diabetologia Date: 2018-10-11 Impact factor: 10.122
Authors: David J Cote; John L Kilgallon; Noah L A Nawabi; Hassan Y Dawood; Timothy R Smith; Ursula B Kaiser; Edward R Laws; JoAnn E Manson; Meir J Stampfer Journal: J Clin Endocrinol Metab Date: 2022-03-24 Impact factor: 5.958
Authors: Renato Cozzi; Maria Rosaria Ambrosio; Roberto Attanasio; Claudia Battista; Alessandro Bozzao; Marco Caputo; Enrica Ciccarelli; Laura De Marinis; Ernesto De Menis; Marco Faustini Fustini; Franco Grimaldi; Andrea Lania; Giovanni Lasio; Francesco Logoluso; Marco Losa; Pietro Maffei; Davide Milani; Maurizio Poggi; Michele Zini; Laurence Katznelson; Anton Luger; Catalina Poiana Journal: Eur J Endocrinol Date: 2022-02-03 Impact factor: 6.664